

Name of the Issue: **Mankind Pharma Limited**

- 1 Type of Issue (IPO/FPO)** IPO
- 2 Issue Size (Rs. Cr)** 43,263.55*
* As per Basis of Allotment
- 3 Grade of issue alongwith name of the rating agency**
Name Not Applicable
Grade Not Applicable
- 4 Subscription Level (Number of times):** 15.4631*
*Based on valid applications (excluding Anchor investors, duplicate and multiple bids)
Source: Minutes of Basis of Allotment dated May 03, 2023

5 QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	%
(i) allotment in the issue*	5.28%
(ii) at the end of the 1st Quarter immediately after the listing of the issue	4.18%
(iii) at the end of 2nd FY (March 31, 2024)	21.01%
(iv) at the end of 3rd FY (March 31, 2025)#	Not Available

* As per the Basis of Allotment dated May 03, 2023

QIB Holding not disclosed as reporting for relevant period / fiscal years have not been completed/ not publicly available
Source:

(1) Basis of Allotment

(2) Reported to the stock exchanges;

6 Financials of the issuer (as per the annual financial results submitted to stock exchanges)

(Rs. Lakhs)

Parameters (Consolidated)	1st FY (March 31, 2024)	2nd FY (March 31, 2025) ⁽¹⁾	3rd FY (March 31, 2026) ⁽¹⁾
Income from operations	1,033,477.46	Not Available	Not Available
Net Profit for the period	194,177.17	Not Available	Not Available
Paid-up equity share capital	4,005.88	Not Available	Not Available
Reserves excluding revaluation reserves	932,302.93	Not Available	Not Available

⁽¹⁾ Financials not disclosed as reporting for the fiscal year has not been completed/ not publicly available

7 Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both, the BSE Limited and the National Stock Exchange of India Limited.
The Shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2025)*	Not Applicable
(iii) at the end of 3rd FY (March 31, 2026)*	Not Applicable

* Trading status not disclosed as the relevant fiscal year has not been completed.

8 Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	Mr. Ramesh Juneja	Re-appointed as Chairman and Whole-time Director
	Mr. Rajeev Juneja	Re-appointed as Vice Chairman and Managing Director
	Mr. Sheetal Arora	Re-appointed as whole-time Director and Chief Executive Officer
(ii) at the end of 2nd FY (March 31, 2025)*	Not Available	Not Available
(iii) at the end of 3rd FY (March 31, 2026)*	Not Available	Not Available

As per the website of BSE and NSE

* Changes in Directors not disclosed as the relevant fiscal year has not been completed.

9 Status of implementation of project/ commencement of commercial production

- (i) as disclosed in the offer document - Not applicable as 100% OFS
- (ii) Actual implementation - Not Applicable
- (iii) Reasons for delay in implementation, if any - Not Applicable

10 Status of utilization of issue proceeds

- (i) as disclosed in the offer document - Not applicable as 100% OFS
- (ii) Actual utilization - Not applicable
- (iii) Reasons for deviation, if any - Not Applicable

11 Comments of monitoring agency, if applicable

Not Applicable

12 Pricing Data

Issue Price (Rs.): 1,080
Designated Stock Exchange: NSE
Listing Date: 9-May-23

Price parameters	At close of listing day (9-May-2023)	At close of 30th calendar day from listing day ⁽¹⁾	At close of 90th calendar day from listing day ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2024) ⁽³⁾		
				Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	1,422.30	1,733.80	1,880.60	2,300.8	2,336.4	1,322.7
Nifty 50	18,264.40	18,726.40	19,517.00	22,326.9	22,493.6	17,398.1
Sectoral Index	N.A.	N.A.	N.A	N.A	N.A	N.A

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2025) ⁽⁴⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2026) ⁽⁴⁾		
	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price (on NSE)	N.A	N.A	N.A	N.A	N.A	N.A
Nifty 50	N.A	N.A	N.A	N.A	N.A	N.A
Sectoral Index	N.A	N.A	N.A	N.A	N.A	N.A

Source: NSE Website
Company is not part of any sectoral index

(1) 30th calendar day has been taken as listing date plus 29 calendar days, except where 30th,calendar day is a holiday, in which case we have considered the closing data of the next trading day
(2) 90th calendar day has been taken as listing date plus 89 calendar days, except where 30th,calendar day is a holiday, in which case we have considered the closing data of the next trading day
(3) High and Low based on intra day prices
(4) Pricing data not disclosed as the relevant fiscal year has not completed.

13 Basis for Issue Price

Accounting ratio	As disclosed in the prospectus dated April 28, 2023	At the end of 1st FY (March 31, 2024)	At the end of 2nd FY (March 31, 2025)#	At the end of 3rd FY (March 31, 2026)#	
Diluted EPS (Rs.)	Issuer:	35.78	47.68	Not Available	Not Available
	Peer Group & Industry Average:	78.00	88.83	Not Applicable	Not Applicable
	Sun Pharmaceuticals Industries Limited	13.60	39.90	Not Applicable	Not Applicable
	Cipla Limited	31.17	51.10	Not Applicable	Not Applicable
	Zydus Lifesciences Limited	43.83	38.14	Not Applicable	Not Applicable
	Torrent Pharmaceutical Limited	22.97	48.94	Not Applicable	Not Applicable
	Alkem Laboratories	137.63	150.19	Not Applicable	Not Applicable
	JB Chemicals & Pharmaceuticals Limited	49.82	34.85	Not Applicable	Not Applicable
	Eris Lifesciences Limited	29.88	28.79	Not Applicable	Not Applicable
	Ipca Laboratories Limited	34.85	21.57	Not Applicable	Not Applicable
	Abbott India Limited	375.86	565.28	Not Applicable	Not Applicable
	Glaxosmithkline Pharmaceuticals Limited	100.04	34.83	Not Applicable	Not Applicable
	Dabur India Limited	9.81	10.38	Not Applicable	Not Applicable
	Procter & Gamble Health Limited	116.00	Not Available	Not Applicable	Not Applicable
	Zydus Wellness Limited	48.54	41.94	Not Applicable	Not Applicable
	P/E(x)	Issuer:	30.18	48.25	Not Available
Peer Group & Industry Average:		40.16	42.17	Not Applicable	Not Applicable
Sun Pharmaceuticals Industries Limited		71.54	40.62	Not Applicable	Not Applicable
Cipla Limited		28.18	29.35	Not Applicable	Not Applicable
Zydus Lifesciences Limited		10.95	26.41	Not Applicable	Not Applicable
Torrent Pharmaceutical Limited		66.25	53.14	Not Applicable	Not Applicable

	Alkem Laboratories	23.03	32.90	Not Applicable	Not Applicable
	JB Chemicals & Pharmaceuticals Limited	39.48	47.36	Not Applicable	Not Applicable
	Eris Lifesciences Limited	19.10	29.29	Not Applicable	Not Applicable
	Ipca Laboratories Limited	22.38	57.37	Not Applicable	Not Applicable
	Abbott India Limited	56.19	47.98	Not Applicable	Not Applicable
	Glaxosmithkline Pharmaceuticals Limited	57.03	55.98	Not Applicable	Not Applicable
	Dabur India Limited	54.55	50.40	Not Applicable	Not Applicable
	Procter & Gamble Health Limited	42.27	Not Available	Not Applicable	Not Applicable
	Zydus Wellness Limited	31.11	35.18	Not Applicable	Not Applicable
RoNW (%)	Issuer⁽¹⁾:	23.29	20.74	Not Available	Not Available
	Peer Group & Industry Average:	21.78	18.62	Not Applicable	Not Applicable
	Sun Pharmaceuticals Industries Limited	6.82	15.04	Not Applicable	Not Applicable
	Cipla Limited	12.08	15.55	Not Applicable	Not Applicable
	Zydus Lifesciences Limited	26.40	19.46	Not Applicable	Not Applicable
	Torrent Pharmaceutical Limited	13.06	24.15	Not Applicable	Not Applicable
	Alkem Laboratories	19.05	17.57	Not Applicable	Not Applicable
	JB Chemicals & Pharmaceuticals Limited	18.06	18.90	Not Applicable	Not Applicable
	Eris Lifesciences Limited	21.28	15.35	Not Applicable	Not Applicable
	Ipca Laboratories Limited	16.10	8.36	Not Applicable	Not Applicable
	Abbott India Limited	28.32	32.48	Not Applicable	Not Applicable
	Glaxosmithkline Pharmaceuticals Limited	63.64	33.19	Not Applicable	Not Applicable
	Dabur India Limited	20.75	18.36	Not Applicable	Not Applicable
	Procter & Gamble Health Limited	31.23	Not Available	Not Applicable	Not Applicable
	Zydus Wellness Limited	6.38	4.98	Not Applicable	Not Applicable
NAV per share based on last balance sheet	Issuer⁽¹⁾:	153.65	265.35	Not Available	Not Available
	Peer Group & Industry Average:	368.06	435.80	Not Applicable	Not Applicable
	Sun Pharmaceuticals Industries Limited	200.10	265.35	Not Applicable	Not Applicable
	Cipla Limited	258.32	330.78	Not Applicable	Not Applicable
	Zydus Lifesciences Limited	166.05	197.07	Not Applicable	Not Applicable
	Torrent Pharmaceutical Limited	175.89	202.58	Not Applicable	Not Applicable
	Alkem Laboratories	722.44	862.46	Not Applicable	Not Applicable

JB Chemicals & Pharmaceuticals Limited	240.83	188.37	Not Applicable	Not Applicable
Eris Lifesciences Limited	140.39	190.12	Not Applicable	Not Applicable
Ipca Laboratories Limited	216.47	249.59	Not Applicable	Not Applicable
Abbott India Limited	1,327.00	1,740.71	Not Applicable	Not Applicable
Glaxosmithkline Pharmaceuticals Limited	157.19	104.93	Not Applicable	Not Applicable
Dabur India Limited	47.41	55.68	Not Applicable	Not Applicable
Procter & Gamble Health Limited	371.39	Not Available	Not Applicable	Not Applicable
Zydus Wellness Limited	761.26	841.95	Not Applicable	Not Applicable

Source:

* All the financial information for the Company above is on a restated and consolidated basis.

** All the financial information for listed industry peers mentioned above is on a consolidated basis (unless otherwise available only on standalone basis) and is sourced from the financial statements of the respective company for the year ended March 31, 2022 submitted to the Stock Exchanges.

*** P/E Ratio for the Company has been computed based on the Offer Price of ₹ 1,080 per Equity Share divided by the Diluted EPS as at March 31, 2022.

Notes:

(1) Sourced from Prospectus dated April 28, 2023.

(2) Information not provided as the relevant fiscal year has not completed or data not available

(3) For Procter & Gamble Health Limited the latest financial statements are for the year ended June 30, 2022. Accordingly, Diluted EPS, RoNW and NAV pertain to year ended June 30, 2022.

14 Any other material information

Particulars	Date
Listing of equity shares of Mankind Pharma Limited	9-May-23
Resignation of Director (Mr. Leonard Lee Kim, Non-Executive Director of the Company with effect from May 9, 2023	9-May-23
Exchange has sought clarification from Mankind Pharma Ltd on May 11, 2023, with reference to news appeared in economictimes.indiatimes.com dated May 11, 2023 quoting "I-T dept raids Mankind Pharma premises in Delhi over tax evasion allegation"	11-May-23
Company informed stock exchanges that the IT Dept is conducting search at the offices of the Company located in New Delhi and Navi Mumbai, at the plants of the Company located at Paonta Sahib, Himachal Pradesh and South Sikkim, Sikkim, and at the plants of Relax Pharmaceuticals Private Limited, Copmed Pharmaceuticals Private Limited and Pharmaforce Labs (subsidiaries of the Company), located at Paonta Sahib, Himachal Pradesh. The officials of the Company and subsidiaries are cooperating with the officials of the IT Dept and are responding to the	12-May-23
Company informed stock exchanges that Income Tax Department ("IT Dept") conducted search under the Income Tax Act, 1961 at some of the offices and plants of the Company and its subsidiaries. Company has fully cooperated with the officials of IT Dept during the proceedings and responded to the clarifications and details sought by them.	17-May-23
Reappointment of Mr. Ramesh Juneja (DIN: 00283399) as Chairman and Whole-time Director (Key Managerial Personnel) of the Company for the period of five (5) years w.e.f. May 15, 2024 to May 14, 2029 (both days inclusive) upon completion of his present tenure	2-Aug-23
Reappointment of Mr. Rajeev Juneja (DIN: 00283481) as Vice Chairman and Managing Director (Key Managerial Personnel) of the Company for the period of five (5) years w.e.f. May 15, 2024 to May 14, 2029 (both days inclusive) upon completion of his present tenure	
Reappointment of Mr. Sheetal Arora (DIN: 00704292) as Whole-time Director and Chief Executive Officer (Key Managerial Personnel) of the Company for the period of five (5) years w.e.f. May 15, 2024 to May 14, 2029 (both days inclusive) upon completion of his present tenure	
Company informed that the Board of Directors of the Company in their meeting held on August 24, 2023 have approved the incorporation of a wholly owned subsidiary by the name Mankind Medicare Private Limited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs.	24-Aug-23
Company has been changed from U74899DL1991PLC044843 to L74899DL1991PLC044843 in the records of the Ministry of Corporate Affairs, Government of India to reflect the listing status of the Company. The Company will update the new CIN wherever applicable in due course.	31-Aug-23

Commercial operations with respect to pharmaceutical formulations has commenced at the Company's newly set-up plant in Udaipur, Rajasthan with effect from i.e. September 25, 2023	25-Sep-23
Informed that operations at our manufacturing facility at Daring Block, Berimok, Namchi Zilla, South Sikkim have been disrupted due to disturbance in power/utility supply because of flash floods in river Teesta, since late night of October 04, 2023. There is no major disruption expected in supply chain as the manufacturing of the products have been diverted to other plants. The business operations of the Company continued as usual as the other plants are fully operational.	5-Oct-23
Appointed of Mr. Prateek Dubey as President – Global Chief Human Resource Officer (being Senior Management Personnel) w.e.f. October 16, 2023.	16-Oct-23
Company informed that they are in receipt of request letter dated October 27, 2023, from M/s. EzeRx Health Tech Private Limited, (enclosed herewith as Annexure) requesting reclassification from "Promoter and Promoter Group" Category to "Public" Category in terms of the provisions of Regulation 31A of the SEBI Listing Regulations. The said request will be placed before the board of directors in their ensuing meeting for their consideration and the Company will take all other necessary approvals in terms of Regulations 31A of the SEBI Listing Regulations.	28-Oct-23
The scheme of Amalgamation ("Scheme") between Shree Jee Laboratory Private Limited, JPR Labs Private Limited and Jaspack Industries Private Limited, wholly owned subsidiaries of the Company, with the Company and their respective shareholders and creditors subject to requisite approvals/consents under sections 230 to 232 and other applicable provisions of Companies Act, 2013	31-Oct-23
Company has submitted an application to BSE Limited and National Stock Exchange of India Limited for reclassification of EzeRx Health Tech Private Limited from Promoter & Promoter Group Category to Public Category pursuant to the provisions of Regulation 31A(3) of the Listing Regulations.	27-Nov-23
Company has made investment of GBP 999,900 in Actimed Therapeutics Limited ("Actimed") on December 15, 2023.	15-Dec-23
In accordance with the requirement of Rule 19(2)(b) and 19(A) of Securities Contracts (Regulation) Rules, 1957 and Regulation 38 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with para 3(7)(i) of the SEBI Circular No. SEBI/HO/CFD/PoD2/P/CIR/2023/18 dated February 3, 2023 ("Circular") in connection with manner of achieving minimum public shareholding, Company informed the details with respect to the intention of the Mr. Sheetal Arora, Mr. Arjun Juneja and Mrs. Puja Juneja, Promoter and Promoter Group members of the Company for sale of Equity Shares of the Company	7-Feb-24
This is with reference to our earlier intimation dated February 7, 2024, we wish to inform you that Mr. Sheetal Arora, Mr. Arjun Juneja and Mrs. Puja Juneja, Promoter and Promoter Group members of Mankind Pharma Limited (the "Company"), informed the Company that they have sold 18,17,070; 24,01,128 and 22,71,336 equity shares respectively aggregating to 64,89,534 equity shares of the Company having face value of ₹ 1 each (representing 1.62 % of the total issued and paid-up equity share capital of the Company) on February 8, 2024, in accordance with SEBI Circular No. SEBI/HO/CFD/PoD2/P/CIR/2023/18 dated February 3, 2023 to achieve the Minimum Public Shareholding requirement.	9-Feb-24
Application made by the Company to BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on November 27, 2023 regarding reclassification of EzeRx Health Tech Private Limited from "Promoter and Promoter Group" Category to "Public" Category, we wish to inform you that the Company has received the approval from BSE and NSE for such reclassification in accordance with provisions of Regulation 31A of the Listing Regulations on March 04, 2024.	5-Mar-24
Mankind Pharma Limited & AstraZeneca Pharma India Limited have signed today Distribution and Promotion agreement for the distribution of budesonide and formoterol fumarate dihydrate (brand name Symbicort).	11-Mar-24
Slump sale of the Over the Counter ("OTC") Business of the Company to Wholly Owned Subsidiary Company proposed to be incorporated with the name of Mankind Consumer Products Private Limited or any other name as approved by Ministry of Corporate Affairs. The transaction will be effective on or before October 1, 2024 or such other date as may be mutually agreed between the parties, subject to customary closing conditions. The Company will continue to have business operations with the proposed incorporated entity on arm's length basis.	2-Apr-24
Increase in authorized share capital of the Company from ₹ 41,35,00,000/- (Forty-One Crore Thirty Five Lacs Only) divided into 41,35,00,000/- (Forty-One Crore Thirty Five Lacs) Equity Shares of ₹ 1/- each to ₹ 60,00,00,000/- (Rupees Sixty Crore only) divided into 60,00,00,000 (Sixty Crore) Equity Shares of ₹ 1/- each and consequential alteration in the Capital Clause of the Memorandum of Association.	15-May-24
Raising of funds by way of issuance of such number of equity shares having face value of ₹ 1 each of the Company ("Equity Shares") and / or other eligible securities or any combination thereof (hereinafter referred to as "Securities"), for an aggregate amount not exceeding ₹ 7,500 crores (Rupees Seven Thousand Five Hundred Crores only) or an equivalent amount thereof by way of issuance of equity / equity linked securities under qualified institutional placement ("QIP") or through issuance of FCCBs, ADRs / GDRs / debt securities or through any other permissible mode in accordance with the applicable laws, subject to the receipt of the necessary approvals including the approval of the members of the Company and other regulatory / statutory approvals, as may be required.	

The Board of Directors of the Company at its meeting held today i.e. July 25, 2024, has considered and approved the acquisition of 100% stake in Bharat Serums and Vaccines Limited (BSV) subject to completion of customary conditions and receipt of requisite regulatory approvals pursuant to the terms and conditions of (a) the Share Purchase Agreement dated July 25, 2024 amongst the Company, BSV and the sellers i.e. Ansamira Limited and Miransa Limited, Affiliates of funds managed by Advent International, and (b) Share Purchase Agreement dated July 25, 2024 amongst Company, BSV and certain minority shareholders i.e. Bhaskar Iyer and Abhijit Mukherjee (collectively referred as "Share Purchase Agreements").	25-Jul-24
Informd that the Nomination and Remuneration Committee of the Board of Directors of the Company vide circular resolution passed today i.e. August 14, 2024, has allotted 9,000 equity shares of face value of Re. 1/- each of the Company to the eligible employees who have exercised their options pursuant to Employees Stock Option Plan 2022 ("ESOP 2022").	14-Aug-24
Company has received an Order on August 26, 2024 from Office of Deputy Commissioner of State, Nagpur, Maharashtra ("Department") imposing a penalty of Rs. 20,000/- under applicable provisions of the CGST Act, 2017.	26-Aug-24
Company has received an Order on August 26, 2024 from Office of Deputy Commissioner, Mohali, Punjab ("Department") imposing a penalty of Rs. 50,000/- under applicable provisions of the CGST Act, 2017	26-Aug-24
Company has executed the Business Transfer Agreement ("BTA") on September 3, 2024 to transfer Over the Counter (OTC) Business Undertaking (defined in the BTA) of the Company as a going concern on a slump sale basis to Mankind Consumer Products Private Limited (MCPPL), a wholly owned subsidiary of the Company. The completion of slump sale of OTC Business Undertaking to MCPPL is subject to pre-conditions, closing actions and other terms and conditions as specified in the BTA.	3-Sep-24
Board of Directors of the Company will be held on September 20, 2024, inter-alia to consider and approve the raising of funds by way of issue of non-convertible debentures, commercial papers, other debt securities or any other security or any combination thereof for an amount as may be decided by the Board	17-Sep-24
Company has completed the transfer of Over the Counter (OTC) Business Undertaking (defined in the BTA) of the Company as a going concern on a slump sale basis to Mankind Consumer Products Private Limited (MCPPL), a wholly owned subsidiary of the Company on September 30, 2024	30-Sep-24
Mankind Pharma Limited (the "Company") along with its wholly owned subsidiary, Appian Properties Private Limited has completed the acquisition of 100% stake of Bharat Serums and Vaccines Limited ("BSV") on October 23, 2024 for a cash consideration of INR 13,768 Crores as per the terms and conditions of the share purchase agreement dated July 25, 2024 (including amendments thereto) entered into between the	23-Oct-24
Alteration of Articles of Association of the Company by inserting a new article to authorize Debenture Trustee(s) to nominate a person to be appointed as a director on the Board of the Company in exercise of its duties under the Securities and Exchange Board of India (Debenture Trustees) Regulations, 1993 read with the Securities and Exchange Board of India (Issue and Listing of Non-Convertible Securities) Regulations, 2021 (together "SEBI Regulations"), as amended from time to time and the Board shall appoint such person as a nominee director, subject to the approval of the Members of the Company	5-Nov-24
Mr. Pradeep Chugh, Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company, has submitted his resignation to pursue career opportunity outside the Organization. The Board accepted and acknowledged his resignation during its meeting on November 5, 2024 and Mr. Pradeep Chugh will be relieved from his duties with effect from the close of business hours on November 30, 2024.	5-Nov-24
Nomination and Remuneration Committee of the Board of Directors of the Company vide circular resolution passed today i.e. November 8, 2024, has allotted 18,000 equity shares of face value of Re. 1/- each of the Company to the eligible employees who have exercised their options pursuant to Employees Stock Option Plan 2022 ("ESOP 2022")	8-Nov-24
disposal of the Company's partnership interest in Mankind Specialties to Vascare Sciences Private Limited, a Company incorporated under the Companies Act, 1956 for a lumpsum consideration of approximately ₹ 4 Crores.	3-Dec-24
appointment of Mr. Ashish Mittal (ICSI Membership No. A25169) as Company Secretary and Compliance officer of the Company and Key Managerial Personnel and designated as Deputy Company Secretary with effect from December 3, 2024, as recommended by Nomination and Remuneration Committee.	3-Dec-24
Board of Directors approved Raising of funds aggregating up to ₹ 3,000 crores (Indian Rupees Three Thousand Crores only) by way of Qualified Institutions Placement ("QIP") under applicable laws, including the Companies Act, 2013 read with the rules notified thereunder and Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, by way of issuance of such number of equity shares having a face value of ₹ 1 each of the Company	12-Dec-24

Fund Raising Committee of Directors of the Company at its meeting held today i.e. December 20, 2024 approved the allotment of 1,19,04,761 Equity Shares of face value of ₹1 each to the eligible Qualified Institutional Buyers at the issue price of ₹2,520/- per Equity Share, i.e. at a premium of ₹ 2519/- per Equity Share aggregating to ₹ 29,99,99,97,720/- pursuant to the Issue.	20-Dec-24
resignation of Mr. Ashish Mittal from the position of Company Secretary and Compliance Officer of the Company w.e.f. the close of business hours on January 8, 2025, as part of internal re-structuring. Mr. Mittal will continue to work with the Company at his earlier position i.e. Assistant General Manager- Secretarial;	8-Jan-25
appointment of Mr. Hitesh Kumar Jain (ICSI Membership No. F6241) as Company Secretary and Compliance officer of the Company and Key Managerial Personnel w.e.f. January 9, 2025, as recommended by Nomination and Remuneration Committee;	
Board of Directors of the Company vide circular resolution passed today i.e. February 4, 2025, has allotted 11,628 equity shares of face value of Re. 1/- each of the Company to the eligible employee who has exercised the options pursuant to the ESOP Plan.	4-Feb-25
Board appointed Committee of Independent Directors in its meeting held today i.e. February 10, 2025 approved the sale of entire stake held by the Company in Mahananda Spa and Resorts Private Limited ("Mahananda"), a Wholly Owned Subsidiary Company to Chalet Hotels Limited. The proceeds of monetization of non-core assets to be utilized to retire part of its debts,	10-Feb-25

Source: Stock Exchange filings; For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com